Generiques et article 38a OPAS: quel impact? [Generic drugs and legal incentives: which impact?]

Détails

ID Serval
serval:BIB_6747553D6285
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Generiques et article 38a OPAS: quel impact? [Generic drugs and legal incentives: which impact?]
Périodique
Revue Médicale Suisse
Auteur(s)
Livio  F., Buclin  T., Pannatier  A., Biollaz  J.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
04/2006
Volume
2
Numéro
61
Pages
966-9
Notes
English Abstract
Journal Article --- Old month value: Apr 12
Résumé
The dispositions that regulate generic substitution in Switzerland have been recently revised, and impose definite incentives on prescribers. The benefits and drawbacks associated with the prescription of generic drugs are reviewed, considering the viewpoints of patients, practitioners and third party payers. While the initial prescription of a generic drug raises no specific concerns, the generic switch during long-term treatment may require some caution. The advantages of using International Nonproprietary Names (INN) for drug prescription are discussed. A renewal of prescription habits would be welcomed however several practical issues would have to find rational solutions.
Mots-clé
*Drugs, Generic *Legislation, Drug Prescriptions, Drug Switzerland
Pubmed
Création de la notice
25/01/2008 10:58
Dernière modification de la notice
20/08/2019 15:22
Données d'usage